🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to researchers.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with figures suggesting more than 82 million instances per year. Especially elevated rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, marketed under the name a brand name, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This places it at an equal footing with the current standard treatment, which uses two antibiotics. The research enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals directly involved have expressed positive views. Having a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is deemed crucial to reduce the burden of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.